Biogen Inc. (BIIB)

Statement of Cash Flows

Difficulty: Beginner

The cash flow statement provides information about a company’s cash receipts and cash payments during an accounting period, showing how these cash flaws link the ending cash balance to the beginning balance shown on the company’s statement of financial position.

The cash flow statement consists of three parts: cash flows provided by (used in) operating activities, cash flows provided by (used in) investing activities, and cash flows provided by (used in) financing activities.

Biogen Inc., Consolidated Statement of Cash Flows

USD $ in thousands

	12 months ended	Dec 31, 2018		Dec 31, 2017		Dec 31, 2016		Dec 31, 2015		Dec 31, 2014
	Net income
	Depreciation, amortization and impairments
	Acquired in-process research and development
	Share-based compensation
	Deferred income taxes
	Contingent consideration
	Other
	Accounts receivable
	Due from anti-CD20 therapeutic programs
	Inventory
	Other assets
	Accrued expenses and other current liabilities
	Income tax assets and liabilities
	Other liabilities
	Changes in operating assets and liabilities, net
	Adjustments to reconcile net income to net cash flows from operating activities
	Net cash flows provided by operating activities
	Proceeds from sales and maturities of marketable securities
	Purchases of marketable securities
	Contingent consideration related to Fumapharm AG acquisition
	Acquired in-process research and development
	Acquisitions of businesses, net of cash acquired
	Purchases of property, plant and equipment
	Acquisitions of intangible assets
	Purchase of Ionis Pharmaceuticals, Inc. stock
	Investment in Samsung Bioepis
	Other
	Net cash flows used in investing activities
	Purchase of treasury stock
	Proceeds from (payments related to) issuance of stock for share-based compensation arrangements, net
	Net distribution to noncontrolling interest
	Proceeds from borrowings
	Repayments of borrowings
	Net cash contribution to Bioverativ, Inc.
	Excess tax benefit from share-based compensation
	Contingent consideration payments
	Other
	Net cash flows provided by (used in) financing activities
	Effect of exchange rate changes on cash and cash equivalents
	Net increase (decrease) in cash and cash equivalents
	Cash and cash equivalents, beginning of the year
	Cash and cash equivalents, end of the year

Based on: 10-K (filing date: 2019-02-06), 10-K (filing date: 2018-02-01), 10-K (filing date: 2017-02-02), 10-K (filing date: 2016-02-03), 10-K (filing date: 2015-02-04).

Item	Description	The company
Net cash flows provided by operating activities	Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.	Biogen Inc.’s net cash flows provided by operating activities increased from 2016 to 2017 and from 2017 to 2018.
Net cash flows used in investing activities	Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.	Biogen Inc.’s net cash flows used in investing activities declined from 2016 to 2017 but then increased from 2017 to 2018 exceeding 2016 level.
Net cash flows provided by (used in) financing activities	Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.	Biogen Inc.’s net cash flows provided by (used in) financing activities declined from 2016 to 2017 and from 2017 to 2018.

	Biogen Inc.	Other companies (not purchased previously)
Financial Statements
Common-Size Financial Statements
Ratios
Relative Valuation
Discounted Cash Flow (DCF) Valuation
Economic Value Added (EVA)
Long-term Trends
Analysis
Financial Reporting Quality

	All companies
Financial Statements
Common-Size Financial Statements
Ratios
Relative Valuation
Discounted Cash Flow (DCF) Valuation
Economic Value Added (EVA)
Long-term Trends
Analysis
Financial Reporting Quality